Risk of pneumonia and exacerbations of chronic obstructive pulmonary disease(COPD) with inhaled corticosteroid (ICS) use: a Singapore perspective
K. Koh (Singapore, Singapore), P. Tiew (Singapore, Singapore), J. Tan (Singapore, Singapore), R. Soh (Singapore, Singapore), K. Tan (Singapore, Singapore), T. Ong (Singapore, Singapore), M. Koh (Singapore, Singapore), S. Chotirmall (Singapore, Singapore), T. Lapperre (Singapore, Singapore)
Source: International Congress 2018 – Pharmacological management of COPD
Session: Pharmacological management of COPD
Session type: Thematic Poster
Number: 769
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Koh (Singapore, Singapore), P. Tiew (Singapore, Singapore), J. Tan (Singapore, Singapore), R. Soh (Singapore, Singapore), K. Tan (Singapore, Singapore), T. Ong (Singapore, Singapore), M. Koh (Singapore, Singapore), S. Chotirmall (Singapore, Singapore), T. Lapperre (Singapore, Singapore). Risk of pneumonia and exacerbations of chronic obstructive pulmonary disease(COPD) with inhaled corticosteroid (ICS) use: a Singapore perspective. 769
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: